Memantine
Cognitive · NMDA antagonist
Tier A
Bottom line
Read Off Label grades Memantine as A (8.0/10) based on strong evidence, med benefit magnitude, and a low-risk safety profile.
Approved for moderate-to-severe AD; modest effect sizes on ADCS-ADL.
Studied, labeled, or reported-use context: 5-20 mg/day PO titrated — Rx; not individualized guidance.
What the evidence says
Approved for moderate-to-severe AD; modest effect sizes on ADCS-ADL. Off-label uses include augmentation in OCD and neuropathic pain. Healthy-person nootropic use is poorly studied and is not an approved indication; higher doses may produce cognitive blunting.
Mechanism
Low-affinity, uncompetitive NMDA receptor antagonist; blocks pathologic tonic glutamate activation while preserving physiologic bursts; also 5-HT3 and nicotinic antagonism
Studied, labeled, or reported dose & route
5-20 mg/day PO titrated
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Memantine's effects?
- Read Off Label rates the evidence for Memantine as Strong and the benefit magnitude as med, producing an overall grade of A (8.0/10). Approved for moderate-to-severe AD; modest effect sizes on ADCS-ADL.
- What safety findings are reported for Memantine?
- Memantine has a low risk profile in the database. Low (well-tolerated; dizziness, headache) Legal status: Rx.
- What doses or routes are reported for Memantine?
- 5-20 mg/day PO titrated This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Memantine work?
- Low-affinity, uncompetitive NMDA receptor antagonist; blocks pathologic tonic glutamate activation while preserving physiologic bursts; also 5-HT3 and nicotinic antagonism
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.